Shopping cart ITEMS
 modern scholarly publishers in the finest tradition
Login Register
Home
Books
Journals
References
A-Z Index
Author Index
For Our Authors
User Area
Shopping Cart
Contact
Electronic Data Center

Journal of Environmental Pathology, Toxicology and Oncology

 

ISSN for PRINT: 0731-8898

Institutional price:

$672.00

Issues per year:

4

For Online Access

Best Paper Award Selection - Editorial Board Site

Add subscription to shopping cart

2006, Volume25

Issue 1-2

  546 pages  

   

click 'Save as...' here to save XML metadata

Issue price - $344.00  

Add to shopping cart

  • Photoimmunotherapy for Cancer Treatment
  • Wei R. Chen
    Department of Physics and Engineering, University of Central Oklahoma, 100 North University Drive, Edmond, OK 73034

    Zheng Huang
    HealthOne Alliance, 899 Logan Street, Suite 203, Denver, CO 80203

    Mladen Korbelik
    British Columbia Cancer Agency, British Columbia Cancer Research Centre, 601 West 10th Avenue, Vancouver BC, V5Z 1L3 Canada

    Robert E. Nordquist
    Wound Healing of Oklahoma, Inc., 3945 North Walnut Street, Oklahoma, City, OK 73015

    Hong Liu
    Center for Bioengineering and School of Electrical and Computer Engineering, University of Oklahoma, Norman, OK 73019


    ABSTRACT

    Phototherapy, with its effective dose control and light delivery, has become a promising modality for treating malignant and nonmalignant diseases. Photochemical interaction, specifically photodynamic therapy (PDT), and photothermal interaction have been the primary mechanisms for direct cell destruction in the treatment of cancers. Preclinical studies demonstrate that, in addition to direct local cytotoxicity, PDT can also induce systemic immune responses, which may enhance therapeutic effects on primary tumors and on metastases at distant sites. Selective photothermal therapy, using an in situ application of light-absorbing dye, has also proven to be an effective method for local treatment of tumors. When combined with immunotherapy, the effects of phototherapy can be amplified, potentially making the photoimmunotherapy a systemic treatment modality. This photother-apy-immunotherapy combination, particularly in conjunction with immunoadju-vant, has been used in preclinical studies. The efficacy and long-term effects of such a combination are summarized and the recent experimental results are presented. A new immunoadjuvant, glycated chitosan (GC), has been used to enhance photochemical and photothermal therapies. The PDT-GC combination in the treatment of mammary tumors and lung tumors in mice provided significant improvement in the long-term survival of tumor-bearing animals. The use of GC in dye-assisted laser photothermal therapy also provided long-term curative effects and antitumor immune responses in the treatment of metastatic tumors in rats. The immune responses induced by phototherapy and enhanced by immunotherapy could become important mechanism in the control of metastatic tumors.

    Download article, 281-292 pages

    Article price - $35.00  

    Add to shopping cart

    << Previous article   Next article >>

    Designed by offsiteteam Designed by offsiteteam Designed by offsiteteam
    Begell House Inc.
    50 Cross Highway,
    Redding, CT 06896
    TEL (203) 938 1300
    FAX (203) 938 1304
    orders@begellhouse.com